Peptide Reference

5-Amino-1MQ: The NNMT Inhibitor Studied for Fat Cell Metabolism

A focused reference on mechanism, research dosing ranges, and what the mouse and cell-culture data actually shows.

Last reviewed September 3, 2026 4 min read By Dave Belmonte, Founder
5-Amino-1MQ NNMT Inhibitor Metabolic Research
Back to Expert Insights

What Is 5-Amino-1MQ and How Does It Work

5-Amino-1MQ is a synthetic small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme expressed at elevated levels in white adipose tissue. Worth noting up front: 5-Amino-1MQ is not a peptide - it's a methylquinolinium small molecule - though it is commonly marketed and sold alongside peptides in the research chemical space, which is why it shows up in peptide-focused catalogs and guides.

NNMT normally diverts nicotinamide away from the NAD+ salvage pathway, converting it to 1-methylnicotinamide (1-MNA) via a reaction that consumes S-adenosylmethionine (SAM). By competitively inhibiting NNMT, 5-Amino-1MQ is studied for its ability to keep more nicotinamide available for recycling into NAD+ through NAMPT, while preserving intracellular SAM. In adipocyte and mouse models, this shift has been associated with suppressed lipogenesis, reduced adipocyte size, and lower body weight - a proposed mechanism for reducing fat cell growth and supporting metabolic rate that does not rely on stimulant activity.

Research Dosing

There is no clinically validated human dosing protocol for 5-Amino-1MQ. The figures below combine what the foundational animal research used with what is commonly cited in research-community protocols - these are not equivalent sources, and neither constitutes medical guidance.

Source Dose Frequency Route
Foundational mouse study 20mg/kg 3× daily, 11 days SubQ injection (animal model)
Commonly cited research-community range ~50–150mg/day (hedged - not a validated clinical dose) 1–2× daily, 8–12 week cycles Oral capsule

Context: The 20mg/kg subcutaneous mouse dose does not translate directly to a human oral equivalent. The 50-150mg/day oral range circulating in research-community protocols is a convention drawn from vendor and community sources rather than a published, peer-reviewed human dosing trial - treat it as a loosely established starting reference, not a validated figure.

Regulatory Status

5-Amino-1MQ has not been evaluated or approved by the FDA for any human indication, and it is not currently listed on the FDA's 503A or 503B bulk drug substance lists for compounding pharmacies. Products sold as "5-Amino-1MQ" - including the one carried in the BioStackIQ shop - are marketed and sold as research chemicals for laboratory and research use only, not for human consumption. This is a legal distinction, not a safety endorsement: research-use framing does not indicate that a product has been evaluated by any regulator for human safety or efficacy. Consult a qualified healthcare provider before considering any research compound protocol.

What Research Shows

The evidence base for 5-Amino-1MQ is preclinical. The compound was developed and characterized as a selective, membrane-permeable NNMT inhibitor and tested in diet-induced obese mice, where it reduced body weight and white adipose mass, lowered plasma cholesterol, and decreased adipocyte size without changing food intake - alongside supporting in vitro adipocyte data showing increased NAD+ and SAM and suppressed lipogenesis. No completed human clinical trials of 5-Amino-1MQ have been published, so claims about human fat loss or metabolic-rate effects remain extrapolations from animal and cell-culture data rather than confirmed human outcomes.

Research reference: Neelakantan H, Vance V, Wetzel MD, et al. "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochem Pharmacol. 2018;147:141-152. PMID: 29155147. View on PubMed

For a broader look at how metabolic-support compounds are sequenced alongside other research peptides, see the peptide stack beginner's guide. For the full preclinical evidence breakdown, see 5-Amino-1MQ Human Studies: Mouse Data, No Human Trials Yet. For price and COA checks, see where to buy 5-Amino-1MQ.

Frequently Asked Questions

What is 5-Amino-1MQ?

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme elevated in white adipose tissue. By blocking NNMT, it is studied for its ability to preserve intracellular NAD+ and reduce fat cell growth without stimulant-driven mechanisms. It is technically a synthetic small molecule rather than a peptide, though it is commonly sold alongside peptides in the research chemical market.

What's the typical research dose?

There is no clinically established human dose. The foundational mouse study used 20mg/kg administered subcutaneously three times daily. Separately, research-community protocols commonly cite oral doses in the range of 50-150mg per day, often split into two doses, over cycles of roughly 8-12 weeks - this range comes from community convention, not peer-reviewed human dosing trials.

Is 5-Amino-1MQ legal to purchase?

5-Amino-1MQ has not been evaluated or approved by the FDA for any human use. It is sold by suppliers as a research chemical for laboratory research use only, not for human consumption. It is not listed on the FDA's 503A or 503B bulk drug substance lists for compounding pharmacies.

Has 5-Amino-1MQ been tested in humans?

No completed human clinical trials of 5-Amino-1MQ have been published. The published evidence base is preclinical: a 2018 study in diet-induced obese mice and supporting in vitro adipocyte data. Any human effects remain unconfirmed by controlled trials.

How is 5-Amino-1MQ different from a stimulant fat burner?

Stimulant-based fat burners typically work by raising catecholamines to increase energy expenditure. 5-Amino-1MQ's proposed mechanism is metabolic rather than stimulant-driven - it inhibits NNMT to preserve NAD+ and SAM pools inside fat cells, which in mouse models suppressed lipogenesis and reduced adipocyte size without increasing food intake or requiring stimulant activity.

Disclaimer: This content is for informational purposes only. 5-Amino-1MQ is a research compound not approved by the FDA for human use, and published efficacy data is limited to animal and cell-culture studies. Always consult a qualified healthcare provider before starting any research compound protocol. Nothing in this article constitutes medical advice.